Flora Growth Signs Letter of Intent to Enter Panama, Applauds Recent Cannabis Law Reforms
Flora Growth Corp. (NASDAQ: FLGC) has signed a Letter of Intent with Robust Farms Inc., a Panamanian distributor, to supply cannabinoid products through its Kasa Wholefoods division. This follows the recent passage of Bill 153 in Panama, legalizing medical cannabis, which will allow pharmacies to distribute licensed medical cannabis and derivatives. The new law also restricts licenses for production to seven manufacturers. The partnership marks a significant step towards expanding Flora's presence in Central America and providing patients with access to medical-grade cannabis products.
- Signed a Letter of Intent with Robust Farms Inc. for cannabinoid product distribution.
- Recent legislative changes in Panama create a regulatory framework for medical cannabis, opening access to new markets.
- None.
-
Flora signs Letter of Intent with an international importer and distributor based in
Panama to provide cannabinoid containing food and beverages through its Kasa Wholefoods division, and finished cannabis derivative products for medical cannabis patients
-
Recent passage of cannabis legislative in
Panama legalizes the use of medical cannabis and creates regulatory framework to monitor and control access.
- Pharmacies will be responsible for the distribution of medical cannabis products and will need to apply for a permit and pass a site inspection (valid initially for two years)
- Domestic production will take place, though only seven licenses for the manufacturing of cannabis seeds, plants, and derivatives will be granted
On
- Patients that have been authorized to use medical cannabis based on specific clinical indications will have the right to access medical cannabis products through licensed pharmacies
- Domestic production will take place, though only seven licenses for the manufacturing of cannabis seeds, plants, and derivatives will be granted
- Pharmacies will be responsible for the distribution of medical cannabis products and will need to apply for a permit and pass a site inspection (valid initially for two years)
- The creation of the National Program for the Study of the Medicinal Use of Cannabis and its Derivatives to promote research and develop educational campaigns
- There is no provision for at home cultivation
- Advertising may only appear in scientific journals, not the media or social networks
“It’s important to recognize the continued trend of medical and adult-use cannabis legalization sweeping across the globe as governments increasingly recognize its therapeutic properties, and want to control, regulate, and tax these products to foster economic prosperity, as well as bring significant reform in civil rights and criminal justice,” said
“We’re extremely pleased to enter into this agreement with Flora in order to pre-emptively secure access to their medical-grade cannabis products – which we believe is the first of its kind to be announced since the cannabis legislation passed – and look forward to supplying our clients with Flora’s premium portfolio of CBD-infused and non-CBD food and beverage products in the short term,” said
Upcoming CEO Fireside Chat
Flora is also pleased to announce that it will be hosting another live fireside discussion between President & CEO,
Registration Link:
https://us02web.zoom.us/webinar/register/WN_eRv8cruzS66PSh6FvOV4hA
Specifically, Luis, Jason, and James will provide an overview of the recent Colombian legislative changes and timeline, including discussing the receipt of our export quota, international markets, and our near-term and long-term international product roadmap. An update will be provided regarding the proposed acquisition of
About
Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.floragrowth.ca or follow @floragrowthcorp on social for more information.
Cautionary Statement Concerning Forward-Looking Statements
This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: Flora’s supply chain strategy; the size of markets for cannabis and cannabis products; our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this document and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005333/en/
Investor Relations Contact:
evan.veryard@floragrowth.ca
Public Relations Contact:
+1 (858) 264-6600
flora@cmwmedia.com
Source:
FAQ
What is the recent development involving Flora Growth Corp (FLGC) in Panama?
What does Bill 153 in Panama entail for medical cannabis?
How many licenses for cannabis production are allowed in Panama?
What products will Flora Growth supply to Panama?